The Anti Asthma Drugs Market is anticipated to reach USD 24,417.88 Million by 2030 at 4.90% CAGR during the forecast period 2022-2030.

With the air pollution rising around the world, the number of asthma patients is also increasing. Therefore, the market for the drugs necessary for its treatment is rising.

Observing the market structure, this report evaluates the future growth potential of the market and analyses the strategies of the key players in the market. It also follows the competitive developments such as joint ventures, new product developments, mergers and acquisitions, new product developments (R & D) in the Anti Asthma Drugs Market. According to this report, the key factors that drive this growth of this market include growing awareness of the benefits of modern drug therapy, the great potential of biologics, growth in patients due to increasing pollution, and problems arising from consumerism & unhealthy lifestyles. Constraints that can make the market growth hit a roadblock are the fear among leading drug brands regarding the loss of patents of leading brands and increasing fragmentation of markets and generic penetration.

Key Players

The key Anti Asthma Drugs Market Players include

AstraZeneca PLC (UK), Boehringer Ingelheim (Germany), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline PLC (UK), Merck & Co. Inc. (USA), Novartis International AG (Switzerland), Sunovion Pharmaceuticals Inc (USA), and Teva Pharmaceutical Industries (Israel).


The global Anti Asthma Drugs Market Insights has been segmented based on drug class, route of administration, therapy, trigger, types of asthma and lastly, region.

·         Based on drug class, this market has been segmented into bronchodilators, corticosteroids, leukotriene antagonists, mast cell stabilizers, monoclonal antibody, and others. Bronchodilators have been further segmented into anticholinergics, beta agonists, and Xanthines.

·         Based on the route of administration, the market has been segmented into inhaled, intravenous, oral, and subcutaneous.

·         The therapy-based segmentation of market comprises of curative therapy and preventive therapy.

·         The trigger-based segmentation of the market covers adult-onset asthma, child-onset asthma, cough-induced asthma, exercise-induced asthma, nocturnal asthma, occupational asthma, steroid-resistant asthma.

·         By type, the market has been segmented into allergic (extrinsic) asthma and non-allergic (intrinsic) asthma.

·         The regional segmentation of the global anti-asthma drugs market segments the market into regional markets namely The Americas (North America & South America), Europe, Asia Pacific, the Middle East & Africa (MEA). Due to the availability of advanced medical facilities, North America is not only a bigger market than South America, but it is also the biggest market for anti-asthma drugs. In this region, the biggest country-wide market is the United States of America (USA). Many key players in the market are based here. 

Europe is the second largest market as it is also equipped with advanced medical facilities. The cream of the Anti Asthma Drugs Market Outlook in this region covers, like France, Germany, Italy, Spain, and the United Kingdom (UK) followed by the rest of Europe. The Asia Pacific is witnessing major newer cases due to greater screening and better health care facilities distribution. During the forecast period, this region is expected to emerge as the fastest growing market. The most important markets in this region are China, India, Japan, and South Korea, followed by the rest of Asia Pacific. The MEA region is a small market due to lack of awareness about anti-asthma, lack of education, lack of technological development, poor healthcare, and healthcare not considered a priority by most governments.

Latest Industry News

·         According to research conducted in the Indian Institute of Science (IISc), Bengaluru, a drug called Pranlukast that is useful for treating asthma, has been found to be effective against tuberculosis. 23 June 2018

·         Morepen Laboratories Ltd. has received approval from the United States Food and Drug Administration (USFDA) for both its bulk drugs manufacturing facilities situated in Himachal Pradesh, India. While the Baddi facility has got approval for the manufacture of the bulk drug “Atorvastatin Calcium,” a Cholesterol reducing drug, the Masulkhana facility has got approval for manufacturing an anti-asthma bulk drug "Montelukast Sodium" for export to the US market. 30 Jul 2018          

Related Report-



About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013